GLP-1 Medications: What American and Global Patients Need to Know About Ozempic, Wegovy, and Mounjaro

Part 1 of 5 | The GLP-1 Series | When Food Meets Medicine

By Dr. Remí Olukoya, PharmD

---

Part 1 of 5 in our GLP-1 series. Coming next: Life After GLP-1 — what happens when the medication stops.

---

Let me be honest with you.

Every week, I fill prescriptions for Ozempic, Wegovy, and Mounjaro. And every week, I watch patients leave the pharmacy with a medication that costs more than their rent — and very little real information about how to use it well.

They have seen the before-and-after photos on Instagram. They have heard the celebrity stories. What they have not heard is the full picture: what these medications actually do inside your body, what you need to eat while you are on them, what the risks are, and — critically — what happens when you stop.

That is what this series is for.

---

What Is a GLP-1 Medication?

GLP-1 stands for glucagon-like peptide-1 — a hormone your body already makes naturally, every time you eat. When food enters your gut, your intestines release GLP-1 into your bloodstream. It travels to your pancreas and tells it to release insulin. It travels to your brain and tells it you are full. It slows down how quickly your stomach empties, so the food you just ate stays with you longer.

In short: GLP-1 is your body's built-in appetite and blood sugar regulator.

GLP-1 receptor agonists — the medications we are talking about — are synthetic versions of this hormone, engineered to last much longer in your body than the natural version does. Where your body's own GLP-1 disappears within minutes, these medications stay active for days or even a week.

The result is a sustained signal to your brain: you are full. A sustained signal to your pancreas: release insulin. And a sustained slowing of gastric emptying that means blood sugar rises more gradually after meals.

---

The Medications: What Is the Difference?

Patients are understandably confused by the names. Here is a clear breakdown:

The key distinction to understand is between semaglutide and tirzepatide. Semaglutide works on one receptor — the GLP-1 receptor. Tirzepatide works on two: the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). That dual action is why tirzepatide tends to produce greater average weight loss in clinical trials — roughly 20–22% of body weight compared to 15% with semaglutide, though individual results vary considerably.

The other distinction worth understanding is between the diabetes-approved versions (Ozempic, Mounjaro) and the weight-management-approved versions (Wegovy, Zepbound). The active ingredient is the same — the difference is the approved dose and the indication on the label. This matters for insurance coverage, which we will address shortly.

---

Who Are These Medications For?

GLP-1 medications are FDA-approved for adults with:

• Type 2 diabetes — to improve blood sugar control alongside diet and exercise
• Chronic weight management — for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol

They are not approved for type 1 diabetes, and they are not a first-line treatment for everyone who wants to lose weight. A proper evaluation by a physician — looking at your full medical history, current medications, and health goals — is essential before starting.

---

What to Eat While You Are on a GLP-1

This is the piece that most online content skips entirely. And it is the piece that determines whether your experience on these medications is manageable or miserable.

Because GLP-1 medications slow gastric emptying — the rate at which food leaves your stomach — certain foods will make you feel significantly worse. High-fat meals are the most common culprit. A greasy burger or a heavy cream-based pasta dish sits in a slowed stomach for a very long time, and the result is prolonged nausea, bloating, and discomfort that can last for hours.

What works best while on a GLP-1:

Lean proteins — chicken, fish, eggs, Greek yogurt, legumes — should anchor every meal. Protein is your most important nutrient on these medications, and I will explain exactly why in Part 2 of this series. For now, know that most patients on GLP-1s are not eating nearly enough of it.

Vegetables and whole grains provide the fiber your slowed digestive system needs to keep moving. Without adequate fiber, constipation — one of the most common side effects — becomes a real problem.

Fruits are valuable but should be eaten in moderation, particularly for patients managing blood sugar, because of their natural sugar content.

Hydration is non-negotiable. Nausea and reduced appetite make it easy to forget to drink water, but dehydration worsens every GLP-1 side effect.

What to avoid or minimize:

High-fat foods, fried foods, and very large meals are the primary triggers for nausea and vomiting. Alcohol is worth a separate conversation: it slows gastric emptying further, can cause unpredictable blood sugar swings, and interacts poorly with the medication's mechanism. If you drink, do so in moderation and never on an empty stomach.

---

Managing Side Effects

The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and bloating. They are most intense when you first start the medication or when your dose increases, and they typically improve over four to eight weeks as your body adjusts.

The most important thing to know about side effects is this: the dose escalation schedule exists for a reason. Your doctor starts you on a low dose and increases it gradually — usually every four weeks — specifically to minimize these effects. Patients who rush the titration, or who push their doctor to escalate faster, are the ones who end up stopping the medication because the nausea becomes unbearable.

Go slow. Let your body adjust. The results are worth the patience.

For nausea specifically: smaller, more frequent meals work far better than three large ones. Ginger — in tea, in candies, or in capsule form — has genuine evidence behind it for nausea relief. Avoid lying down immediately after eating. And if nausea is severe or persistent, speak to your doctor before the next dose escalation.

---

When to Call Your Doctor Immediately

Most side effects are manageable. But some symptoms require urgent medical attention:

Severe, persistent abdominal pain that radiates to your back may indicate pancreatitis — inflammation of the pancreas. This is rare but serious. Do not wait it out.

Signs of low blood sugar — shaking, sweating, rapid heartbeat, confusion, sudden intense hunger — are most relevant if you are also taking insulin or certain diabetes medications. GLP-1s alone rarely cause hypoglycemia, but in combination with other agents, the risk increases.

Swelling of the face, lips, tongue, or throat; difficulty breathing; or a severe rash are signs of an allergic reaction. Stop the medication and seek emergency care.

Vision changes should be reported to your doctor promptly.

---

Who Should Not Take These Medications

GLP-1 medications are not appropriate for everyone. They should not be used by people with a personal or family history of medullary thyroid carcinoma — a specific type of thyroid cancer — or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are not recommended during pregnancy or breastfeeding. And they require careful consideration in people with a history of pancreatitis or severe gastrointestinal disease.

This is not a medication to start based on a social media post or a telehealth visit with a provider who has not reviewed your full medical history. The clinical relationship matters.

---

The Cost Question: A Global Reality

In the United States, GLP-1 medications without insurance coverage cost between $900 and $1,500 per month. Insurance coverage for diabetes indications is more common; coverage for weight management is inconsistent and often requires prior authorization and documentation of failed lifestyle interventions.

Manufacturer savings programs — available through Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) — can reduce out-of-pocket costs significantly for commercially insured patients. Patients without insurance face a much harder road. Ask your pharmacist about every available option before assuming you cannot afford it.

Globally, the picture is uneven. In the United Kingdom and much of Western Europe, semaglutide is available through national health systems for diabetes, with weight management coverage expanding. In Canada, provincial coverage varies. In Australia, the Pharmaceutical Benefits Scheme covers it for diabetes with restrictions. In many lower-income countries, access remains limited and cost is prohibitive — a disparity that reflects a broader inequity in who gets to benefit from medical innovation.

---

The Bottom Line

GLP-1 medications are genuinely powerful tools. They are not magic, and they are not a substitute for the lifestyle work that makes results last. But for the right patient, used correctly, they can change the trajectory of chronic disease in a way that very few medications can.

What they require from you is this: the right food choices, the patience to let your body adjust, the discipline to stay connected with your healthcare team, and the honesty to understand that the medication creates the window — but what you do in that window determines whether the results last.

In Part 2 of this series, we are going to talk about what happens when the medication stops. Because the weight regain data is real, and the patients who navigate that transition well are the ones who prepared for it.

---

Eat smart. Your meds matter. Your body will love you for it.

— Dr. Remí Olukoya, PharmD PharmaPlan Systems | pharmaplansystems.com

---

Resources:

• PharmaPlan GLP-1 Meal Plan: pharmaplansystems.com
• MediMeal Safe AI Assistant — food-drug interaction checker: pharmaplansystems.com
• When Food Meets Medicine book: pharmaplansystems.com

Sources: FDA Prescribing Information for Ozempic, Wegovy, Mounjaro, and Zepbound | American Diabetes Association Standards of Care 2024 | NEJM: Semaglutide and Cardiovascular Outcomes (SELECT Trial, 2023) | NEJM: Tirzepatide for Obesity (SURMOUNT-1, 2022)